Lipids and cognition

Journal of Alzheimer's Disease

Volumn 20, Issue 3, 2010, Pages 737-747

  Morley, John E ^a   Banks, William A ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; amyloid protein; blood brain barrier; cholesterol; elderly; leptin; lipids; obesity; omega 3 fatty acids; triglycerides

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E4; ARACHIDONIC ACID; CHOLESTEROL; CHOLINESTERASE INHIBITOR; DOCOSAHEXAENOIC ACID; GAMMA SECRETASE; GASTROINTESTINAL HORMONE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 1 RECEPTOR TYPE II; INTERLEUKIN 6; LEPTIN; LIPID; MESSENGER RNA; OMEGA 3 FATTY ACID; PLACEBO; PRAVASTATIN; SATURATED FATTY ACID; SIMVASTATIN; STRESS ACTIVATED PROTEIN KINASE; TAU PROTEIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; CENTRAL NERVOUS SYSTEM; CLINICAL ASSESSMENT; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; COGNITIVE DEVELOPMENT; DEMENTIA; EXPERIMENTAL MOUSE; EXPERIMENTAL RAT; FISH; GENETIC RISK; GERBIL; HUMAN; HYPERTRIGLYCERIDEMIA; IMMUNOREACTIVITY; LIPID PEROXIDATION; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; NONHUMAN; OBESITY; OXIDATIVE STRESS; PLANT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SPATIAL MEMORY; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 77954554644     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-091576     Document Type: Review

References (137)

1. Sparks DL, Scheff SW, Hunsaker JC III, Liu H, Landers T, Gross DR (1994) Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 126, 88-94.
2. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, Duff K, Pappolla MA (2000) Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7, 321-331.
3. Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, Thomas-Bryant T, Tint GS, Wang R, Mercken M, Petanceska SS, Duff KE (2001) A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 8, 890-899.
4. Burns MP, Noble WJ, Olm V, Gaynor K, Casey E, LaFrancois J, Wang L, Duff K (2003) Co-localization of cholesterol, apolipoprotein E and fibrillar Abeta in amyloid plaques. Brain Res Mol Brain Res 110, 119-125.
5. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S, Bertsch T, von Bergmann K, Hennerici M, Beyreuther K, Hartmann T (2001) Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A 98, 5856-5861.
6. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K (1998) Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A 95, 6460-6464.
7. Mizuno T, Nakata M, Naiki H, Michikawa M,Wang R, Haass C, Yanagisawa K (1999) Cholesterol-dependent generation of a seeding amyloid beta-protein in cell culture. J Biol Chem 274, 15110-15114.
8. Sun ZX, Zhou QH, Sui SF (2005) Cholesterol depletion inhibits the degradation of amyloid beta-peptide in rat pheochromocytoma (PC12) cells. Neurosci Lett 391, 71-75.
9. Stefani M, Liguri G (2009) Cholesterol in Alzheimer's disease: unresolved questions. Curr Alzheimer Res 6, 15-29.
10. Ma T, Zhao Y, Kwak YD, Yang Z, Thompson R, Luo Z, Xu H, Liao FF (2009) Statin's excitoprotection is mediated by sAPP and the subsequent attenuation of calpain-induced truncation events, likely via rho-ROCK signaling. J Neurosci 29, 11226-11236.
11. Guardia-Laguarta C, Coma M, Pera M, Clarimon J, Sereno L, Agullo JM, Molina-Porcel L, Gallardo E, Deng A, Berezovska O, Hyman BT, Blesa R, Gomez-Isla T, Lleo A (2009) Mild cholesterol depletion reduces amyloid-beta production by impairing APP trafficking to the cell surface. J Neurochem 110, 220-230.
12. Wray S, NobleW(2009) Linking amyloid and tau pathology in Alzheimer's disease: the role of membrane cholesterol in Abeta-mediated tau toxicity. J Neurosci 29, 9665-9667.
13. Yamauchi K, Tozuka,M, Nakabayashi T, Sugano M, Hidaka H, Kondo Y, Katsuyama T (1999) Higher avidity binding of apolipoprotein (E-AII) complex than of apolipoprotein E monomer to beta-amyloid. J Neurosci Res 58, 301-307.
14. Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, Zlokovic BV (2007) Transport pathways for clearance of human Alzheimer's amyloid peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab 27, 909-918.
15. Martel CL, Mackic JB, Matsubara E, Governale S, Miguel C, Miao W, McComb JG, Frangione B, Ghiso J, Zlokovic BV (1997) Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer's amyloid beta. J Neurochem 69, 1995-2004.
16. Zlokovic BV, Martel CL, Mackic JB, Matsubara E, Wisniewski T, McComb JG, Frangione B, Ghiso J (1994) Brain uptake of circulating apolipoproteins J and E complexed to Alzheimer's amyloid beta. Biochem Biophys Res Commun 205, 1431-1437.
17. Zlokovic BV (1996) Cerebrovascular transport of Alzheimer's amyloid beta and apolipoproteins J and E: possible anti-amyloidogenic role of the blood-brain barrier. Life Sci 59, 1483-1497.
18. Zlokovic BV, Martel CL, Matsubara E, McComb JG, Zheng G, McCluskey RT, Frangione B, Ghiso J (1996) Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid at the blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci U S A 93, 4229-4234.
19. Shayo M, McLay RN, Kastin AJ, Banks WA (1996) The putative blood-brain barrier transporter for the amyloid binding protein apolipoprotein J is saturated at physiological concentrations. Life Sci 60, L115-L118.
20. Lauderback CM, Hackett JM, Keller JN,Varadarajan S, Sweda L, Kindy M, Markesbery WR, Butterfield DA (2001) Vulnerability of synaptosomes from Apoe knock-out mice to structural and oxidative modifications induced by A beta(1- 40): implications for Alzheimer's disease. Biochemistry 40, 2548-2554.
21. Lauderback CM, Kanski J, Hackett JM, Maeda N, Kindy MS, Butterfield DA (2002) Apolipoprotein E modulates Alzheimer's A (1-42)-induced oxidative damage to synaptosomes in an allele-specific manner. Brain Res 924, 90-97.
22. Lange Y, Ye J, Rigney M, Steck TL (1999) Regulation of endoplasmic reticulum cholesterol by plasma membrane cholesterol. J Lipid Res 40, 2264-2270.
23. Bjorkhem I, Diczfalusy U, Lutjohann D (1999) Removal of cholesterol from extrahepatic sources by oxidative mechanisms. Curr Opin Lipidol 10, 161-165.
24. Lutjohann D, Papassotiropoulos A, Bjorkhem I, Locatelli S, Bagli M, Oehring RD, Schlegel U, Jessen F, Rao ML, von Bergmann K, HeunR(2000) Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J Lipid Res 41, 195-198.
25. Mok VC, Lam WW, Fan YH, Wong A, Ng PW, Tsoi TH, Yeung V, Wong KS (2009) Effects of statins on the progression of cerebral white matter lesion: Post hoc analysis of the ROCAS (Regression of Cerebral Artery Stenosis) study. J Neurol 256, 750-757.
26. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Iivonen S, Mannermaa A, Tuomilehto J, Nissinen A, Soininen H (2002) Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 137, 149-155.
27. Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, Tuomilehto J, Nissinen A (1998) Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 17, 14-20.
28. Jarvik GP, Wijsman EM, Kukull WA, Schellenberg GD, Yu C, Larson EB (1995) Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 45, 1092-1096.
29. Elias PK, Elias MF, D'Agostino RB, Sullivan LM, Wolf PA (2005) Serum cholesterol and cognitive performance in the Framingham Heart Study. Psychosom Med 67, 24-30.
30. Dufouil C, Richard F, Fievet N, Dartigues JF, Ritchie K, Tzourio C, Amouyel P, Alperovitch A (2005) APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. Neurology 64, 1531-1538.
31. Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE (2007) Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med 5, 20.
32. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57, 1439-1443.
33. Yaffe K, Barrett-Connor E, Lin F, Grady D (2002) Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 59, 378-438
34. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA (2000) Statins and the risk of dementia. Lancet 356, 1627-1631.
35. Fonseca AC, Resende R, Oliveira CR, Pereira CM (2009) Cholesterol and statins in Alzheimer's disease: Current controversies. Exp Neurol, in press.
36. Cramer C, Haan MN, Galea S, Langa KM, Kalbfleisch JD (2008) Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 71, 344-350.
37. Rockwood K, Kirkland S, Hogan DB, MacKnight C, Merry H, Verreault R, Wolfson C, McDowell I (2002) Use of lipidlowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 59, 223-227.
38. Santanello NC, Barber BL, Applegate WB, Elam J, Curtis C, Hunninghake DB, Gordon DJ (1997) Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study. J Am Geriatr Soc 45, 8-14.
39. Arvanitakis Z, Schneide JA,Wilson RS, Bienias JL,Kelly JF, Evans DA, Bennett DA (2008) Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology 70, 1795-1802.
40. Heart Protective Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22.
41. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360, 1623-1630.
42. Packard CJ, Westendorp RG, Stott DJ, Caslake MJ, Murray HM, Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hylan M, Jukema JW, Kamper AM, Macfarlane PW, Jolles J, Perry IJ, Sweeney BJ, Twomey C (2007) Association between apolipoprotein E4 and cognitive decline in elderly adults. J Am Geriatr Soc 55, 1777-1785.
43. McGuinness B, Craig D, Bullock R, Passmore P (2009) Statins for the prevention of dementia. Cochrane Database Syst Rev, CD003160.
44. Morley JE, Farr SA, Banks WA, Johnson SN, Yamada KA, Xu L (2009) A Physiological Role for Amyloid-beta Protein: Enhancement of Learning and Memory. J Alzheimers Dis 19, 441-449.
45. Farr SA, Uezu K, Flood JF, Morley JE (1999) Septohippocampal drug interactions in post-trial memory processing. Brain Res 847, 221-230.
46. Bading JR, Yamada S, Mackic JB, Kirkman L, Miller C, Calero M, Ghiso J, Frangione B, Zlokovic BV (2002) Brain clearance of Alzheimer's amyloid-040 in the squirrel monkey: A SPECT study in a primate model of cerebral amyloid angiopathy. J Drug Targeting 10, 359-368.
47. Ito S, Ohtsuki S, Terasaki T (2006) Functional characterization of the brain-to-blood efflux clearance of human amyloidbeta peptide (1-40) across the rat blood-brain barrier. Neurosci Res 56, 246-252.
48. Ghersi-Egea JF, Gorevic PD, Ghiso J, Frangione B, Patlak CS, Fenstermacher,JD (1996) Fate of cerebrospinal fluidborne amyloid-peptide: rapid clearance into blood and appreciable accumulation by cerebral arteries. J Neurochem 67, 880-883.
49. Dohgu S, Banks WA (2008) Lipopolysaccharide-enhanced transcellular transport of HIV-1 across the blood-brain barrier is medited by the p38 mitogen-activated protein kinase pathway. Exp Neurol 210, 740-749.
50. Banks WA, Robinson SM, Verma S, Morley JE (2003) Efflux of human and mouse amyloid proteins 1-40 and 1-42 from brain: Impairment in a mouse model of Alzheimer's disease. Neuroscience 121, 487-492.
51. Deane R,Wu Z, Sagare A, Davis J, Du Yan S,Hamm K, Xu F, Parisi M, LaRue B, HuHW, Spijkers P, Guo H, Song X, Lenting PJ, Van Nostrand WE, Zlokovic BV (2004) LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43, 333-344.
52. Deane R,Wu Z, Zlokovic BV (2004) RAGE(yin) versus LRP (yang) balance regulates Alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 35, 2628-3263
53. Jaeger JB, Dohgu S, Hwang MC, Farr SA, Murphy MP, Fleegal-DeMotta MA, Lynch JL, Robinson SM, Niehoff ML, Johnson SN, Kumar VB, Banks WA (2009) Testing the neurovascular hypothesis of Alzheimer's disease: LRP-1 antisense reduced blood-brain barrier clearance, increases brain levels of amyloid beta protein, and impairs cognition. J Alzheimers Dis 17, 553-570.
54. Zlokovic BV, Yamada S, Holtzman D, Ghiso J, Frangione B (2000) Clearance of amyloid-peptide from brain: transport or metabolism? Nature Med 6, 718-719.
55. Monro OR, Mackic JB, Yamada S, Segal MB, Ghiso J, Maurer C, Calero M, Frangione B, Zlokovic BV (2002) Substitution at codon 22 reduces clearance of Alzheimer's amyloidbeta peptide from the cerebrospinal fluid and prevents its transport from the central nervous system into blood. Neurobiol Aging 23, 405-412.
56. Jaeger LB, Dohgu S, Lynch JL, Fleegal-DeMotta MA, Banks WA (2009) Effects of lipopolysaccharide on the blood-brain barrier transport of amyloid beta protein: A mechanism for inflammation in the progression of Alzheimer's disease. Brain, Behav Immun 23, 507-517.
57. Bell RD, Deane R, Chow N, Long X, Sagare A, Singh I, Streb JW, Guo H, Rubio A, Van Nostrand W, Miano JM, Zlokovic BV (2009) SRF and myocardin regulate LRPmediated anyloid-beta clearance in brain vascular cells. Nat Cell Biol 11, 143-153.
58. Carrie I, Clement M, De JavelD, Frances H, Bourre JM(2000) Specific phospholipid fatty acid composition of brain regions in mice. Effects of n-3 polyunsaturated fatty acid deficiency and phospholipid supplementation. J Lipid Res 41, 465-472. (Pubitemid 30183629)
59. Cahill L, Haier RJ, Fallon J, Alkire MT, Tang C, Keator D, Wu J, McGaugh JL (1996) Amygdala activity at encoding correlated with long-term, free recall of emotional information. Proc Natl Acad Sci U S A 93, 8016-8021.
60. Carrie I, Guesnet P, Bourre JM, Frances H (2000) Diets containing long-chain n-3 polyunsaturated fatty acids affect behaviour differently during development than ageing in mice. Br J Nutr 83, 439-447.
61. Butterfield DA, Drake J, Pocernich C, Castegna A (2001) Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med 7, 548-554.
62. Champeil-Potokar G, Denis I, Goustard-Langelier B, Alessandri JM, Guesnet P, Lavialle M (2004) Astrocytes in culture require docosahexaenoic acid to restore the n-3/n-6 polyunsaturated fatty acid balance in their membrane phospholipids. J Neurosci Res 75, 96-106.
63. LimSY, Suzuki H (2000) Effect of dietary docosahexaenoic acid and phosphatidylcholine on maze behavior and fatty acid composition of plasma and brain lipids in mice. Int J Vitam Nutr Res 70, 251-259.
64. Chung WL, Chen JJ, SuHM(2008) Fish oil supplementation of control and (n-3) fatty acid-deficient male rats enhances reference and working memory performance and increases brain regional docosahexaenoic acid levels. J Nutr 138, 1165-1171.
65. Hooijmans CR, Van Der Zee CE, Dederen PJ, Brouwer KM, Reijmer YD, Van Groen T, Broersen LM, Lutjohann D, Heerschap A, Kiliaan AJ (2009) DHA and cholesterol containing diets influence Alzheimer-like pathology, cognition and cerebral vasculature in APPswe/PS1dE9 mice. Neurobiol Dis 33, 482-498.
66. Hashimoto M, Shahdat HM, Yamashita S, Katakura M, Tanabe Y, Fujiwara H, Gamoh S, Miyazawa T, Arai H, Shimada T, Shido O (2008) Docosahexaenoic acid disrupts in vitro amyloid beta(1-40) fibrillation and concomitantly inhibits amyloid levels in cerebral cortex of Alzheimer's disease model rats. J Neurochem 107, 1634-1646.
67. Ma QL, Yang F, Rosario ER, Ubeda OJ, Beech W, Gant DJ, Chen PP, Hudspeth B, Chen C, ZhaoY,VintersHV, Frautschy SA, Cole GM (2009) Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci 29, 9078-9089.
68. Holguin S, Martinez J, Chow C, Wurtman R (2008) Dietary uridine enhances the improvement in learning and memory produced by administering DHA to gerbils. FASEB J 22, 3938-3946.
69. DargelR(1992) Lipid peroxidation - a common pathogenetic mechanism? Exp Toxicol Pathol 44, 169-181.
70. Green KN, Martinez-Coria H, Khashwji H, Hall EB, Yurko- Mauro KA, Ellis L, LaFerla FM (2007) Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloidbeta and tau pathology via a mechanism involving presenilin 1 levels. J Neurosci 27, 4385-4395.
71. Sakamoto T, Cansev M, Wurtman RJ (2007) Oral supplementation with docosahexaenoic acid and uridine-5'- monophosphate increases dendritic spine density in adult gerbil hippocampus. Brain Res 1182, 50-59.
72. Hashimoto M, Hossain S, Agdul H, Shido O (2005) Docosahexaenoic acid-induced amelioration on impairment of memory learning in amyloid beta-infused rats relates to the decreases of amyloid beta and cholesterol levels in detergentinsoluble membrane fractions. Biochim Biophys Acta 1738, 91-98.
73. Hashimoto M, Tanabe Y, Fujii Y, Kikuta T, Shibata H, Shido O (2005) Chronic administration of docosahexaenoic acid ameliorates the impairment of spatial cognition learning ability in amyloid beta-infused rats. J Nutr 135, 549-555.
74. Sahlin C, Pettersson FE, Nilsson LN, Lannfelt L, Johansson AS (2007) Docosahexaenoic acid stimulates nonamyloidogenic APP processing resulting in reduced Abeta levels in cellular models of Alzheimer's disease. Eur J Neurosci 26, 882-889.
75. Farooqui AA, Horrocks LA, Farooqui T (2007) Modulation of inflammation in brain: a matter of fat. J Neurochem 101, 577-599.
76. Flood JF, Morley JE (1992) Early onset of age-related impairment of aversive and appetitive learning in the SAM-P/8 mouse. J Gerontol 47, B52-B59.
77. Flood JF, Morley JE (1998) Learning and memory in the SAMP8 mouse. Neurosci Biobehav Rev 22, 1-20.
78. Petursdottir AL, Farr SA, Morley JE, Banks WA, Skuladottir GV (2007) Lipid peroxidation in brain during aging in the senescence-accelerated mouse (SAM). Neurobiol Aging 28, 1170-1178.
79. Morley JE, Farr SA, Flood JF (2002) Antibody to amyloid beta protein alleviates impaired acquisition, retention, and memory processing in SAMP8 mice. Neurobiol Learn Mem 78, 125-138.
80. Farr SA, Banks WA, Uezu K, Sano A, Gaskin FS, Morley JE (2003) Antibody to beta-amyloid protein increases acetylcholine in the hippocampus of 12 month SAMP8 male mice. Life Sci 73, 555-562.
81. Morley JE, Kumar VB, Bernardo AF, Farr SA, Uezu K, Tumosa N, Flood JF (2000) Amyloid precursor polypeptide in SAMP8 mice affects learning and memory. Peptides 21, 1761-1767.
82. Poon HF, Farr SA, Banks WA, Pierce WM, Klein JB, Morley JE, Butterfield DA (2005) Proteomic identification of less oxidized brain proteins in aged senescence-accelerated mice following administration of antisense oligonucleotide directed at the Abeta region of amyloid precursor protein. Mol Brain Res 138, 8-13.
83. Poon HF, Joshi G, Sultana R, Farr SA, Banks WA, Morley JE, Calabrese V, Butterfield DA (2004) Antisense directed at the A-beta region of APP decreases brain oxidative markers in aged senescence accelerated mice. Brain Res 1018, 86-96.
84. Farr SA, Poon HF, Dogrukol-Ak D, Drake J, Banks WA, Eyerman E, Butterfield DA, Morley JE (2003) The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J Neurochem 84, 1173-1183.
85. Kumar VB, Wyas K, Buddhiraju M, Alshaher M, Flood JF, Morley JE(1999) Changes inmembrane fatty acids and delta- 9 desaturase in senescence accelerated (SAMP8) mouse hippocampus with aging. Life Sci 65, 1657-1662.
86. Petursdottir AL, Farr SA, Morley JE, Banks WA, Skuladottir GV (2008) Effect of dietary n-3 polyunsaturated fatty acids on brain lipid fatty acid composition, learning ability, and memory of senescence-accelerated mouse. J Gerontol A Biol Sci Med Sci 63, 1153-1160.
87. Kivipelto M, Solomon A (2006) Cholesterol as a risk factor for Alzheimer's disease - epidemiological evidence. Acta Neurol Scand Suppl 185, 50-57.
88. Morris MC, EvansDA, Bienias JL, Tangney CC, BennettDA, Wilson RS, Aggarwal N, Schneider J (2003) Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 60, 940-946.
89. Barberger-Gateau P, Letenneur L, Deschamps V, Peres K, Dartigues JF, Renaud S (2002) Fish, meat, and risk of dementia: cohort study. Br Med J 325, 932-933.
90. Schaefer EJ, Bongard V, Beiser AS, Lamon-Fava S, Robins SJ, Au R, Tucker KL, Kyle DJ, Wilson PW, Wolf PA (2006) Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol 63, 1545-1550.
91. Devore EE, Grodstein F, Van Rooij FJ, Hofman A, Rosner B, Stampfer MJ, Witteman JC, Breteler MM (2009) Dietary intake of fish and omega-3 fatty acids in relation to long-term dementia risk. Am J Clin Nutr 90, 170-176.
92. Van Gelder BM, Tijhuis M, Kalmijn S, Kromhout D (2007) Fish consumption, n-3 fatty acids, and subsequent 5-y cognitive decline in elderly men: the Zutphen Elderly Study. Am J Clin Nutr 85, 1142-1147.
93. Kotani S, Sakaguchi E,Warashina S, Matsukawa N, Ishikura Y, Kiso Y, Sakakibara M, Yoshimoto T, Guo J, Yamashima T (2006) Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci Res 56, 159-164.
94. Van De RO, Geleijnse JM, Kok FJ, Van Staveren WA, Olderikkert MG, Beekman AT, De Groot LC (2009) Effect of fish oil supplementation on quality of life in a general population of older Dutch subjects: a randomized, doubleblind, placebo-controlled trial. J Am Geriatr Soc 57, 1481-1486.
95. Freund-Levi Y, Basun H, Cederholm T, Faxen-Irving G, Garlind A, Grut M, Vedin I, Palmblad J, Wahlund LO, Eriksdotter-Jonhagen M(2008) Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. Int J Geriatr Psych 23, 161-169.
96. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, Basun H, Faxen-Irving G, Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J (2006) Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 63, 1402-1408.
97. Freund-Levi Y, Hjorth E, Lindberg C, Cederholm T, Faxen- Irving G, Vedin I, Palmblad J, Wahlund LO, Schultzberg M, Basun H, Eriksdotter JM (2009) Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dement Geriatr Cogn Disord 27, 481-490.
98. Johnson EJ, McDonald K, Caldarella SM, Chung HY, Troen AM, Snodderly DM (2008) Cognitive findings of an exploratory trial of docosahexaenoic acid and lutein supplementation in older women. Nutr Neurosci 11, 75-83.
99. Cosgrove RG, Arroyo C,Warren JC, Shang J (2009) Impaired cognitive functioning in overweight children and adolescents. Agro Food Indistry Hi-Tech 20, 48-51.
100. EliasMF, Elias PK, Sullivan LM,Wolf PA,&D'AgostinoRB (2003) Lower cognitive function in the presence of obesity and hypertension: the Framingham heart study. Int J Obes Relat Metab Disord 27, 260-268.
101. Jeong SK, Nam HS, Son MH, Son EJ, Cho KH (2005) Interactive effect of obesity indexes on cognition. Dement Geriatr Cogn Disord 19, 91-96.
102. Bruce-Keller AJ, Keller JN, Morrison,CD (2009) Obesity and vulnerability of the CNS. Biochim Biophys Acta 1792, 395-400.
103. Messinger-Rapport BJ, Thomas DR, Gammack JK, Morley JE (2008) Clinical update on nursing home medicine: 2008. J Am Med Dir Assoc 9, 460-475.
104. Meyers RM, Reger L (2009) Diabetes management in longterm care facilities: a practical guide. J Am Med Dir Assoc 10, 589.
105. Joseph J, Koka M, Aronow WS (2008) Prevalence of a hemoglobin A1c less than 70%, of a blood pressure less than 130/80 mm Hg, and of a serum low-density lipoprotein cholesterol less than 100 mg/dL in older patients with diabetes mellitus in an academic nursing home. J Am Med Dir Assoc 9, 51-54.
106. Stranahan AM, Norman ED, Lee K, Cutler RG, Telljohann RS, Egan JM, Mattson MP (2008) Diet-induced insulin resistance impairs hippocampal synaptic plasticity and cognition in middle-aged rats. Hippocampus 18, 1085-1088
107. Perlmuter LC, Nathan DM, Goldfinger SH, Russo PA, Yates J, Larkin,M (1988) Triglyceride levels affect cognitive function in noninsulin-dependent diabetics. J Diabetes Complicat 2, 210-213.
108. Reitz C, Luchsinger J, Tang MX, Manly J, Mayeux R (2005) Impact of plasma lipids and time on memory performance in healthy elderly without dementia. Neurology 64, 1378-1383.
109. Mathew NT, Meyer JS, Achari AN, Dodson RF (1976) Hyperlipidemic neuropathy and dementia. Eur Neurol 14, 370-382.
110. Heilman KM, Fisher WR (1974) Hyperlipidemic dementia. Arch Neurol 31, 67-68.
111. Sims RC, Madhere S, Gordon S, Clark E Jr, Abayomi KA, Callender CO, Campbell AL, Jr (2008) Relationships among blood pressure, triglycerides and verbal learning in African Americans. J Natl Med Assoc 100, 1193-1198.
112. De Frias CM, Bunce D, Wahlin A, Adolfsson R, Sleegers K, Cruts M,Van BroeckhovenC, NilssonLG(2007) Cholesterol and triglycerides moderate the effect of apolipoprotein E on memory functioning in older adults. J Gerontol B Psychol Sci Soc Sci 62, 112-118.
113. Huang CQ, Dong BR, Wu HM, Zhang YL, Wu JH, Lu ZC, Flaherty JH (2009) Association of cognitive impairment with serum lipid/lipoprotein among Chinese nonagenarians and centenarians. Dement Geriatr Cogn Disord 27, 111-116.
114. Atzmon G, Gabriely I, Greiner W, Davidson D, Schechter C, Barzilai N (2002) Plasma HDL levels highly correlate with cognitive function in exceptional longevity. J Gerontol A-Biol 57, M712-M715.
115. Flaherty JH, Shay K, Weir C, Kamholz B, Boockvar KS, Shaughnessy M, Shapiro R, Gordon S, Stein J, Rudolph JL (2009) The development of a mental status vital sign for use across the spectrum of care. J AmMed Dir Assoc 10, 379-380.
116. Eeles E, Rockwood K (2008) Delirium in the long-term care setting: clinical and research challenges. J AmMed Dir Assoc 9, 157-161.
117. Voyer P, Richard S, Doucet L, Carmichael PH (2009) detecting delirium and subsyndromal delirium using different diagnostic criteria among demented long-term care residents. J Am Med Dir Assoc 10, 181-188.
118. Chait A, Robertson HT, Brunzell JD (1981) Chylomicronemia syndrome in diabetes mellitus. Diabetes Care 4, 343-348.
119. Rogers, L, Meyer JS, McClintic K, Mortel KF (1989) Reducing hypertriglyceridemia in elderly patients with cerebrovascular disease stabilizes or improves cognition and cerebral perfusion. Angiology 40, 260-269.
120. Farr SA, Yamada KA, Butterfield DA, Abdul HM, Xu L, Miller NE, Banks WA (2008) Obesity and hypertriglyceridemia produce cognitive impairment. Endocrinology 149, 2628-2636.
121. Morley JE, Farr SA (2008) Cachexia and neuropeptide Y. Nutrition 24, 815-819.
122. Oomura Y, Hori N, Shiraishi T, Fukunaga K, Takeda H, Tsuji M, Matsumiya T, Ishibashi M, Aou S, Li XL, Kohno D, Uramura K, Sougawa H, Yada T, Wayner MJ, Sasaki K (2006) Leptin facilitates learning and memory performance and enhances hippocampal CA1 long-term potentiation and CaMK II phosphorylation in rats. Peptides 27, 2738-2749.
123. Harvey J, Shanley LJ, O'Malley D, Irving AJ (2005) Leptin: a potential cognitive enhancer? Biochem Soc Trans 33, 1029-1032.
124. Farr SA, Banks WA, Morley JE (2006) Effects of leptin on memory processing. Peptides 27, 1420-1425.
125. Oomura Y, Aou S, Fukunaga K (2010) Prandial increase of leptin in the brain activates spatial learning and memory. Pathophysiology 17, 119-127.
126. O'Malley D, MacDonald N, Mizielinska S, Connolly CN, Irving AJ, Harvey J (2007) Leptin promotes rapid dynamic changes in hippocampal dendritic morphology. Mol Cell Neurosci 35, 559-572.
127. Huang JS, Letendre S, Marquie-Beck J, Cherner M, Mc- Cutchan JA, Grant I, Ellis R (2007) Low CSF leptin levels are associated with worse learning and memory performance in HIV-infected men. J Neuroimmune Pharmacol 2, 352-358.
128. Holden KF, Lindquist K, Tylavsky FA, Rosano C, Harris TB, Yaffe K (2009) Serum leptin level and cognition in the elderly: Findings from the Health ABC Study. Neurobiol Aging 30, 1483-1489.
129. Paz-Filho GJ, Babikian T, Asarnow R, Delibasi T, Esposito K, Erol HK,Wong ML, Licinio J (2008) Leptin replacement improves cognitive development. PLoS One 3, e3098.
130. Banks WA, Coon AB, Robinson SM, Moinuddin A, Shultz JM, NakaokeR, Morley JE(2004)Triglycerides induce leptin resistance at the blood-brain barrier. Diabetes 53, 1253-1260.
131. Dagon Y, Avraham Y, Magen I, Gertler A, Ben Hur T, Berry EM (2005) Nutritional status, cognition, and survival: a new role for leptin and AMP kinase. J Biol Chem 280, 42142-42148.
132. Steinberg GR, Bonen A, Dyck DJ (2002) Fatty acid oxidation and triacylglycerol hydrolysis are enhanced after chronic leptin treatment in rats. Am J Physiol 282, E593-E600.
133. Banks WA, Burney BO, Robinson SM (2008) Effects of triglycerides, obesity, and starvation on ghrelin transport across the blood-brain barrier. Peptides 29, 2061-2065.
134. Urayama A, Banks WA (2008) Starvation and triglycerides reverse the obesity-induced impairment of insulin transport at the blood-brain barrier. Endocrinology 149, 3592-3597.
135. Diano S, Farr SA, Benoit, E, McNay EC, da Silva I, Horvath B, Gaskin FS, Nonaka N, Jaeger LB, Banks WA, Morley JE, Pinto S, Sherwin RS, Xu L, Yamada KA, Sleeman MW, Tschop MH, Horvath TL (2006) Ghrelin controls hippocampal spine synapse density and memory performance. Nature Neurosci 9, 381-388.
136. Chang G-Q, Karatayev O, Daydova Z, Leibowitz SF (2006) Circulating triglycerides impact on orexigenic peptides and neuronal activity in hypothalamus. Endocrinology 145, 3904-3912.
137. Jaeger LB, Farr SA, Banks WA, Morley JE (2002) Effects of orexin-A on memory processing. Peptides 23, 1683-1688.